Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Pedro Avila Ribeiro"'
Autor:
Elsa Vieira-Sousa, João Eurico Fonseca, Vasco C Romão, Vítor Teixeira, Rita Cruz-Machado, Maria João Gonçalves, Maria João Saavedra, Pedro Avila-Ribeiro, Ema Sacadura-Leite, André Bento Guerreiro, Ana Valido, Joana Silva-Dinis, Rui Tato Marinho
Publikováno v:
RMD Open, Vol 9, Iss 4 (2023)
Background Hepatitis B virus (HBV) vaccination is recommended for non-immunised patients with rheumatic diseases starting biological disease-modifying antirheumatic drugs (bDMARDs). There is some evidence that HBV vaccination is effective in patients
Externí odkaz:
https://doaj.org/article/fd5c08bf77f044f5acd9c32558c60fbf
Autor:
Johan Askling, Burkhard Möller, Matija Tomšič, Lennart T H Jacobsson, Jakub Zavada, Thorvardur Jon Love, Daniela Di Giuseppe, Adrian Ciurea, Manuel Pombo-Suarez, Maria José Santos, Bjorn Gudbjornsson, Pedro Avila-Ribeiro, Catalin Codreanu, Brigitte Michelsen, Michael John Nissen, Carlos Sánchez-Piedra, Lykke Midtbøll Ørnbjerg, Karen Minde Fagerli, Bente Glintborg, Žiga Rotar, Bénédicte Delcoigne, Gareth T. Jones, Ruxandra Ionescu, Servet Yolbas, Ulf Lindström, Lucie Nekvindová, Heikki Relas, Mikkel Østergaard, Nuh Atas, Florenzo Iannone, Kari K. Eklund
Publikováno v:
Annals of the Rheumatic Diseases
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Lindström, U, Di Giuseppe, D, Delcoigne, B, Glintborg, B, Möller, B, Ciurea, A, Pombo-Suarez, M, Sanchez-Piedra, C, Eklund, K, Relas, H, Gudbjornsson, B, Love, T J, Jones, G T, Codreanu, C, Ionescu, R, Nekvindova, L, Závada, J, Atas, N, Yolbas, S, Fagerli, K M, Michelsen, B, Rotar, Tomšič, M, Iannone, F, Santos, M J, Avila-Ribeiro, P, Ørnbjerg, L M, Østergaard, M, Jacobsson, L T H, Askling, J & Nissen, M J 2021, ' Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration ', Annals of the Rheumatic Diseases, vol. 80, no. 11, 220097, pp. 1410-1418 . https://doi.org/10.1136/annrheumdis-2021-220097
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Lindström, U, Di Giuseppe, D, Delcoigne, B, Glintborg, B, Möller, B, Ciurea, A, Pombo-Suarez, M, Sanchez-Piedra, C, Eklund, K, Relas, H, Gudbjornsson, B, Love, T J, Jones, G T, Codreanu, C, Ionescu, R, Nekvindova, L, Závada, J, Atas, N, Yolbas, S, Fagerli, K M, Michelsen, B, Rotar, Tomšič, M, Iannone, F, Santos, M J, Avila-Ribeiro, P, Ørnbjerg, L M, Østergaard, M, Jacobsson, L T H, Askling, J & Nissen, M J 2021, ' Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration ', Annals of the Rheumatic Diseases, vol. 80, no. 11, 220097, pp. 1410-1418 . https://doi.org/10.1136/annrheumdis-2021-220097
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with
Autor:
Michael Nissen, Bénédicte Delcoigne, Daniela Di Giuseppe, Lennart Jacobsson, Merete Lund Hetland, Adrian Ciurea, Lucie Nekvindova, Florenzo Iannone, Nurullah Akkoc, Tuulikki Sokka-Isler, Karen Minde Fagerli, Maria Jose Santos, Catalin Codreanu, Manuel Pombo-Suarez, Ziga Rotar, Bjorn Gudbjornsson, Irene van der Horst-Bruinsma, Anne Gitte Loft, Burkhard Möller, Herman Mann, Fabrizio Conti, Gozde Yildirim Cetin, Heikki Relas, Brigitte Michelsen, Pedro Avila Ribeiro, Ruxandra Ionescu, Carlos Sanchez-Piedra, Matija Tomsic, Árni Jón Geirsson, Johan Askling, Bente Glintborg, Ulf Lindström
Publikováno v:
Rheumatology, 61, 12, pp. 4741-4751
Nissen, M, Delcoigne, B, Di Giuseppe, D, Jacobsson, L, Hetland, M L, Ciurea, A, Nekvindova, L, Iannone, F, Akkoc, N, Sokka-Isler, T, Fagerli, K M, Santos, M J, Codreanu, C, Pombo-Suarez, M, Rotar, Z, Gudbjornsson, B, van der Horst-Bruinsma, I, Loft, A G, Möller, B, Mann, H, Conti, F, Yildirim Cetin, G, Relas, H, Michelsen, B, Avila Ribeiro, P, Ionescu, R, Sanchez-Piedra, C, Tomsic, M, Geirsson, Á J, Askling, J, Glintborg, B & Lindström, U 2022, ' The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis ', Rheumatology, vol. 61, no. 12, pp. 4741-4751 . https://doi.org/10.1093/rheumatology/keac174
Nissen, M, Delcoigne, B N, di Giuseppe, D, Jacobsson, L, Hetland, M L, Ciurea, A, Nekvindova, L, Iannone, F, Akkoc, N, Sokka-Isler, T, Fagerli, K M, Santos, M J, Codreanu, C, Pombo-Suarez, M, Rotar, Z, Gudbjornsson, B, van der Horst-Bruinsma, I, Loft, A G, Möller, B, Mann, H, Conti, F, Yildirim Cetin, G, Relas, H, Michelsen, B, Avila Ribeiro, P, Ionescu, R, Sanchez-Piedra, C, Tomsic, M, Geirsson, Á J N, Askling, J, Glintborg, B & Lindström, U 2022, ' The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis ', Rheumatology (Oxford, England), vol. 61, no. 12, pp. 4741-4751 . https://doi.org/10.1093/rheumatology/keac174
Rheumatology (Oxford, England), 61(12), 4741-4751. Oxford University Press
Nissen, Michael; Delcoigne, Bénédicte; Di Giuseppe, Daniela; Jacobsson, Lennart; Hetland, Merete Lund; Ciurea, Adrian; Nekvindova, Lucie; Iannone, Florenzo; Akkoc, Nurullah; Sokka-Isler, Tuulikki; Fagerli, Karen Minde; Santos, Maria Jose; Codreanu, Catalin; Pombo-Suarez, Manuel; Rotar, Ziga; Gudbjornsson, Bjorn; van der Horst-Bruinsma, Irene; Loft, Anne Gitte; Möller, Burkhard; Mann, Herman; ... (2022). The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis. Rheumatology, 61(12), pp. 4741-4751. Oxford University Press 10.1093/rheumatology/keac174
Rheumatology, 61, 4741-4751
Nissen, M, Delcoigne, B, Di Giuseppe, D, Jacobsson, L, Hetland, M L, Ciurea, A, Nekvindova, L, Iannone, F, Akkoc, N, Sokka-Isler, T, Fagerli, K M, Santos, M J, Codreanu, C, Pombo-Suarez, M, Rotar, Z, Gudbjornsson, B, van der Horst-Bruinsma, I, Loft, A G, Möller, B, Mann, H, Conti, F, Yildirim Cetin, G, Relas, H, Michelsen, B, Avila Ribeiro, P, Ionescu, R, Sanchez-Piedra, C, Tomsic, M, Geirsson, Á J, Askling, J, Glintborg, B & Lindström, U 2022, ' The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis ', Rheumatology, vol. 61, no. 12, pp. 4741-4751 . https://doi.org/10.1093/rheumatology/keac174
Nissen, M, Delcoigne, B N, di Giuseppe, D, Jacobsson, L, Hetland, M L, Ciurea, A, Nekvindova, L, Iannone, F, Akkoc, N, Sokka-Isler, T, Fagerli, K M, Santos, M J, Codreanu, C, Pombo-Suarez, M, Rotar, Z, Gudbjornsson, B, van der Horst-Bruinsma, I, Loft, A G, Möller, B, Mann, H, Conti, F, Yildirim Cetin, G, Relas, H, Michelsen, B, Avila Ribeiro, P, Ionescu, R, Sanchez-Piedra, C, Tomsic, M, Geirsson, Á J N, Askling, J, Glintborg, B & Lindström, U 2022, ' The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis ', Rheumatology (Oxford, England), vol. 61, no. 12, pp. 4741-4751 . https://doi.org/10.1093/rheumatology/keac174
Rheumatology (Oxford, England), 61(12), 4741-4751. Oxford University Press
Nissen, Michael; Delcoigne, Bénédicte; Di Giuseppe, Daniela; Jacobsson, Lennart; Hetland, Merete Lund; Ciurea, Adrian; Nekvindova, Lucie; Iannone, Florenzo; Akkoc, Nurullah; Sokka-Isler, Tuulikki; Fagerli, Karen Minde; Santos, Maria Jose; Codreanu, Catalin; Pombo-Suarez, Manuel; Rotar, Ziga; Gudbjornsson, Bjorn; van der Horst-Bruinsma, Irene; Loft, Anne Gitte; Möller, Burkhard; Mann, Herman; ... (2022). The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis. Rheumatology, 61(12), pp. 4741-4751. Oxford University Press 10.1093/rheumatology/keac174
Rheumatology, 61, 4741-4751
Objectives Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were to describe the characteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b20aa85f05662083b702b6507faf3bb4
https://repository.ubn.ru.nl/handle/2066/287602
https://repository.ubn.ru.nl/handle/2066/287602
Autor:
Dan Nordström, Bjorn Gudbjornsson, Michael John Nissen, D. Di Giuseppe, Brigitte Michelsen, Manuel Pombo-Suarez, G. Yıldırım Çetin, Pedro Avila-Ribeiro, Karen Minde Fagerli, Catalin Codreanu, Heřman Mann, N. Steen Krogh, Matija Tomšič, Anne Gitte Loft, B. Glintborg, Adrian Ciurea, Heikki Relas, Nurullah Akkoc, L. T. H. Jacobsson, Ulf Lindström, M.L. Hetland, Lucie Nekvindová, I E van der Horst-Bruinsma, Ruxandra Ionescu, Johan Askling, Florenzo Iannone, Arni Jon Geirsson, Carlos Sánchez-Piedra, Gary J. Macfarlane, M. J. Santos, Ziga Rotar, B. Moeller, Bénédicte Delcoigne
Publikováno v:
Annals of the Rheumatic Diseases. 79:71-72
Background:Axial spondylarthritis (axSpA) patients treated with a tumour necrosis factor inhibitor (TNFi) may receive a concomitant conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), although the value of combination therapy rema
Autor:
Mónica Eusébio, Elsa Vieira-Sousa, João Eurico Fonseca, Joana Silva, Maria José Santos, Rita Cruz-Machado, Daniela Santos-Faria, Miguel Bernardes, T. Meirinhos, Nikita Khmelinskii, C. Miguel, Pedro Avila-Ribeiro, Pedro Carvalho, P. Nero, Helena Santos, Ana Catarina Duarte, Tiago Costa, Teresa Martins Rocha
Publikováno v:
The Journal of rheumatology. 47(5)
Objective.To assess longterm effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with psoriatic arthritis (PsA) registered in the Rheumatic Diseases Portuguese Register, exposed to at least 1 TNFi, prospectively followed between 2001
Autor:
Fernando Pimentel-Santos, J. Canas da Silva, R. Fonseca, Pedro Avila-Ribeiro, Helena Canhão, Maria João Salvador, Jaime Branco, Miguel Bernardes, D. van der Heijde, Marcos Cerqueira, Lídia Teixeira, Pedro D. Carvalho, Anabela Barcelos, Alexandre Sepriano, J. Borges, Elsa Vieira-Sousa, Josiane S. Neves, Sofia Ramiro, G. Sequeira, Robert Landewé, Helena Santos, T. Meirinhos
Publikováno v:
Arthritis & Rheumatology. 68:2671-2679
Objective To evaluate whether use of comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) influences the retention of tumor necrosis factor inhibitors (TNFi) in patients with spondyloarthritis (SpA). Methods Patie
Autor:
Florenzo Iannone, D. Di Giuseppe, Karen Minde Fagerli, L. T. H. Jacobsson, Manuel Pombo-Suarez, Thorvardur Jon Love, Kari K. Eklund, Matija Tomšič, Johan Askling, Bénédicte Delcoigne, Mikkel Ǿstergaard, Jakub Zavada, Adrian Ciurea, Servet Yolbas, Bjorn Gudbjornsson, L. Midtbøll Ørnbjerg, Pedro Avila-Ribeiro, Brigitte Michelsen, Catalin Codreanu, B. Glintborg, Gareth T. Jones, Ziga Rotar, B. Moeller, Lucie Nekvindová, M. J. Santos, Heikki Relas, Carlos Sánchez-Piedra, Ruxandra Ionescu, Ulf Lindström, Nuh Atas, Michael John Nissen
Publikováno v:
Annals of the Rheumatic Diseases. 79:729-729
Background:Previous studies have suggested similar effectiveness, but longer treatment retention, for tumor necrosis factor inhibitors (TNFi), when used in combination with a conventional synthetic disease modifying anti-rheumatic drug (csDMARD) in p
Publikováno v:
Current pharmaceutical design. 23(44)
Background biosimilars are similar versions of existing innovator biologic agents but with distinct manufacturing processes. They were approved in inflammatory bowel disease (IBD) by extrapolation of indication from rheumatic diseases. As regulatory
Autor:
Ana Catarina Duarte, Daniela Santos-Faria, Maria João Gonçalves, Alexandre Sepriano, Ana Filipa Mourão, Cátia Duarte, Joana Sousa Neves, Ana Filipa Águeda, Pedro Avila Ribeiro, Alexandra Daniel, Adriano Neto, Ana Cordeiro, Ana Maria Rodrigues, Anabela Barcelos, Cândida Silva, Cristina Ponte, Elsa Vieira-Sousa, Filipa Teixeira, Filipa Oliveira-Ramos, Filipe Araújo, Filipe Barcelos, Helena Canhão, Helena Santos, João Ramos, Joaquim Polido-Pereira, José Tavares-Costa, José António Melo Gomes, Luís Cunha-Miranda, Lúcia Costa, Marcos Cerqueira, Margarida Cruz, Maria José Santos, Miguel Bernardes, Paula Oliveira, Pedro Abreu, Ricardo Figueira, Rita Barros, Sandra Falcao, Patrícia Pinto, Sofia Pimenta, Susana Capela, Vitor Teixeira, João Eurico Fonseca
Publikováno v:
Scopus-Elsevier
CIÊNCIAVITAE
Acta Reumatológica Portuguesa, Vol 2017, Iss 2, Pp 127-140 (2017)
Universidade Nova de Lisboa
CIÊNCIAVITAE
Acta Reumatológica Portuguesa, Vol 2017, Iss 2, Pp 127-140 (2017)
Universidade Nova de Lisboa
BACKGROUND: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::fbf25f5c1bc534204cc7bf2385e2706a
http://www.actareumatologica.pt/archive_detail.php?id=214
http://www.actareumatologica.pt/archive_detail.php?id=214
Publikováno v:
Clinical and experimental rheumatology. 35(5)
In rheumatoid arthritis, quality of sleep and ability to cope are important for patients; however their usefulness as outcome measures is not well established.Post-hoc analysis of an open-label 12-week trial of etanercept in biologic-naïve rheumatoi